This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1987 May:19 Suppl 2:109-21.

doi: 10.1016/s0022-2828(87)80008-1.

Model experiments on anticalcinotic and antiarteriosclerotic arterial protection with calcium antagonists

PMID: 3305965
DOI: 10.1016/s0022-2828(87)80008-1

Review

Model experiments on anticalcinotic and antiarteriosclerotic arterial protection with calcium antagonists

A Fleckenstein. J Mol Cell Cardiol. 1987 May.

. 1987 May:19 Suppl 2:109-21.

doi: 10.1016/s0022-2828(87)80008-1.

Author

PMID: 3305965
DOI: 10.1016/s0022-2828(87)80008-1

No abstract available

PubMed Disclaimer

Similar articles

Arterial calcification and calcium antagonists: what does it mean?
Epstein M, Black HR. Epstein M, et al. Hypertension. 2001 Jun;37(6):1414-5. doi: 10.1161/01.hyp.37.6.1414. Hypertension. 2001. PMID: 11408387 No abstract available.
Antihypertensive, anticalcinotic, and antiarteriosclerotic properties of anipamil, a long-acting new derivative of verapamil.
Frey M, Zorn J, Fleckenstein-Grün G, Fleckenstein A. Frey M, et al. J Cardiovasc Pharmacol. 1989;13 Suppl 4:S23-8. doi: 10.1097/00005344-198900134-00006. J Cardiovasc Pharmacol. 1989. PMID: 2475679 Review.
Calcium--a neglected key factor in arteriosclerosis. The pathogenic role of arterial calcium overload and its prevention by calcium antagonists.
Fleckenstein-Grün G, Fleckenstein A. Fleckenstein-Grün G, et al. Ann Med. 1991;23(5):589-99. doi: 10.3109/07853899109150522. Ann Med. 1991. PMID: 1756029 Review.
Concept of an antiatherosclerotic efficacy of calcium entry blockers. INTACT Investigators.
Jost S, Rafflenbeul W, Deckers J, Wiese B, Hecker H, Nikutta P, Lippolt P, Lichtlen P. Jost S, et al. Eur J Epidemiol. 1992 May;8 Suppl 1:107-19. doi: 10.1007/BF00145361. Eur J Epidemiol. 1992. PMID: 1505647 Review.
[Possibilities in the future application of calcium antagonists. Is the prevention of blood vessel calcinosis possible?].
Fleckenstein A, Frey M, Fleckenstein-Grün G. Fleckenstein A, et al. Fortschr Med. 1984 Jul 26;102(27-28):713-7. Fortschr Med. 1984. PMID: 6479813 German.

See all similar articles

Cited by

Excessive mural calcium overload--a predominant causal factor in the development of stenosing coronary plaques in humans.
Fleckenstein A, Frey M, Thimm F, Fleckenstein-Grün G. Fleckenstein A, et al. Cardiovasc Drugs Ther. 1990 Aug;4 Suppl 5:1005-13. doi: 10.1007/BF02018309. Cardiovasc Drugs Ther. 1990. PMID: 2076386
Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy).
Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Nikutta P, Deckers JW. Lichtlen PR, et al. Cardiovasc Drugs Ther. 1990 Aug;4 Suppl 5:1047-68. doi: 10.1007/BF02018315. Cardiovasc Drugs Ther. 1990. PMID: 2076392 Clinical Trial.
Discovery and Development of Calcium Channel Blockers.
Godfraind T. Godfraind T. Front Pharmacol. 2017 May 29;8:286. doi: 10.3389/fphar.2017.00286. eCollection 2017. Front Pharmacol. 2017. PMID: 28611661 Free PMC article. Review.
A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS).
Grimm RH Jr, Flack JM, Byington R, Bond G, Brugger S. Grimm RH Jr, et al. Drugs. 1990;40 Suppl 2:38-43. doi: 10.2165/00003495-199000402-00011. Drugs. 1990. PMID: 2150640 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information